Intellia Therapeutics Inc. | Key People and Executives
John M. Leonard
President, Chief Executive Officer & Director
Frank A. G. M. Verwiel
Independent Director
Caroline D. Dorsa
Independent Class III Director
Jean-Francois B. Formela
Independent Class I Director
John M. Leonard
President, Chief Executive Officer & Director
Jose E. Rivera
Executive Vice President & General Counsel
Jennifer King
Senior Vice President-Business Development
Thomas M. Barnes
Senior VP-Innovative Sciences & eXtellia
David V. Morrissey
Senior VP-Platform & Delivery Technology
Lindsey Trickett
Vice President-Investor Relations
Jennifer Mound Smoter
Senior VP-External Affairs & Communications
Frank A. G. M. Verwiel
Independent Director
Caroline D. Dorsa
Independent Director
Jean-Francois B. Formela
Independent Director
| Address |
40 Erie Street
Cambridge Massachusetts 02139
United States
|
|
Employees
|
- |
| Website |
http://www.intelliatx.com |
| Updated |
07/08/2019 |
| Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA. |
